Gabriel M.I. Mecklenburg Sells 50,000 Shares of Hinge Health (NYSE:HNGE) Stock

Hinge Health Inc. (NYSE:HNGE) Chairman Gabriel M.I. Mecklenburg sold 50,000 shares of the business’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $65.54, for a total value of $3,277,000.00. Following the completion of the sale, the chairman directly owned 50,000 shares in the company, valued at $3,277,000. This represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Gabriel M.I. Mecklenburg also recently made the following trade(s):

• On Monday, June 1st, Gabriel M.I. Mecklenburg sold 83,334 shares of Hinge Health stock. The stock was sold at an average price of $60.22, for a total value of $5,018,373.48.
• On Tuesday, May 26th, Gabriel M.I. Mecklenburg sold 83,333 shares of Hinge Health stock. The stock was sold at an average price of $53.79, for a total value of $4,482,482.07.
• On Wednesday, May 6th, Gabriel M.I. Mecklenburg sold 50,000 shares of Hinge Health stock. The stock was sold at an average price of $55.01, for a total value of $2,750,500.00.
• On Tuesday, April 21st, Gabriel M.I. Mecklenburg sold 33,333 shares of Hinge Health stock. The stock was sold at an average price of $45.05, for a total value of $1,501,651.65.
• On Wednesday, April 1st, Gabriel M.I. Mecklenburg sold 50,000 shares of Hinge Health stock. The stock was sold at an average price of $38.46, for a total value of $1,923,000.00.

Hinge Health Stock Performance

HNGE opened at $63.48 on Friday. Hinge Health Inc. has a one year low of $30.08 and a one year high of $66.55. The stock’s fifty day moving average is $47.93 and its 200-day moving average is $45.31. The company has a market capitalization of $4.91 billion and a PE ratio of -5.14.

Hinge Health (NYSE:HNGE) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $0.45 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.33. Hinge Health had a negative return on equity of 310.62% and a negative net margin of 78.95%.The company had revenue of $182.31 million for the quarter. During the same period in the prior year, the firm posted $1.30 EPS. The firm’s quarterly revenue was up 47.2% on a year-over-year basis. On average, equities research analysts forecast that Hinge Health Inc. will post 1.21 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of HNGE. Wells Fargo & Company MN grew its holdings in shares of Hinge Health by 160.0% during the fourth quarter. Wells Fargo & Company MN now owns 546 shares of the company’s stock valued at $25,000 after buying an additional 336 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in shares of Hinge Health during the fourth quarter valued at $26,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Hinge Health during the third quarter valued at $37,000. CENTRAL TRUST Co purchased a new position in shares of Hinge Health during the first quarter valued at $37,000. Finally, First Horizon Corp grew its holdings in shares of Hinge Health by 163.9% during the fourth quarter. First Horizon Corp now owns 855 shares of the company’s stock valued at $40,000 after buying an additional 531 shares in the last quarter.

Key Stories Impacting Hinge Health

Here are the key news stories impacting Hinge Health this week:

• Positive Sentiment: Canaccord Genuity raised its price target on Hinge Health to $65 from $63 and reiterated a buy rating, reinforcing a constructive analyst view on the stock. Article Title
• Positive Sentiment: Other recent commentary also stayed upbeat, including technical coverage pointing to a “golden cross,” which can attract momentum investors. Article Title
• Positive Sentiment: Hinge Health’s last earnings report beat estimates, with revenue up 47.2% year over year, supporting the view that the business is still growing rapidly. Article Title
• Neutral Sentiment: One article highlighted Hinge Health as a promising mid-cap healthcare name, but it did not include a new catalyst beyond a generally favorable long-term investment case. Article Title
• Negative Sentiment: Chairman Gabriel M.I. Mecklenburg disclosed another large insider sale of 50,000 shares at $65.54, adding to a series of recent sales and potentially creating some overhang for sentiment. Article Title

Analysts Set New Price Targets

HNGE has been the topic of a number of recent analyst reports. Barclays boosted their target price on Hinge Health from $52.00 to $62.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Royal Bank Of Canada boosted their target price on Hinge Health from $55.00 to $65.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 6th. Evercore reaffirmed an “outperform” rating and set a $45.00 target price on shares of Hinge Health in a research report on Wednesday, April 8th. Truist Financial set a $79.00 target price on Hinge Health in a research report on Wednesday, May 6th. Finally, Needham & Company LLC boosted their target price on Hinge Health from $59.00 to $63.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $67.53.

About Hinge Health

Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company’s platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.